Targeted Therapy in Pancreatic Ductal Adenocarcinoma: Current Advances and Challenges
Current Oncology · 28.07.2026 · 33 (8) · 452
DOI: 10.3390/curroncol33080452 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Current Oncology, online erschienen am 28.07.2026. Verfasst von Ramy Habib und 4 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, University of Limerick, Limerick V94 T9PX, Munster, Ireland. Hauptthemen laut MEDLINE: Carcinoma, Pancreatic Ductal, Molecular Targeted Therapy, Pancreatic Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 180 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal solid malignancies, with poor survival driven by late presentation, aggressive tumor biology, and limited responsiveness to conventional systemic therapy. Advances in molecular profiling have expanded opportunities for biomarker-guided and targeted therapeutic approaches.
Methods
A literature review was conducted using PubMed and the Cochrane Library through July 2026, supplemented by abstracts and proceedings from major international oncology conferences.
Results
Pancreatic cancer is driven mainly by somatic changes in KRAS, TP53, CDKN2A, and SMAD4. Established precision approaches include maintenance olaparib for selected platinum-sensitive tumors with germline BRCA1 or BRCA2 pathogenic variants, immune checkpoint inhibition for mismatch repair-deficient or microsatellite instability-high tumors, and tropomyosin receptor kinase inhibition for cancers with neurotrophic tyrosine receptor kinase gene fusions. Direct inhibition of KRAS and RAS represents a major therapeutic breakthrough. KRAS G12C inhibitors established proof of concept, while agents targeting the more common KRAS G12D mutation are showing encouraging early activity. In the randomized phase III RASolute 302 trial, the multiselective RAS inhibitor daraxonrasib improved survival compared with chemotherapy in previously treated metastatic disease with oncogenic RAS mutations. Early studies of zoldonrasib combinations have extended this progress to KRAS G12D-mutant disease, although confirmation is required. Molecular profiling, next-generation sequencing, patient-derived organoids, and circulating tumor DNA may further improve treatment selection and monitoring.
Conclusions
Precision oncology is becoming clinically relevant in pancreatic ductal adenocarcinoma. KRAS- and RAS-directed therapies are central advances, but resistance, toxicity, limited durability, and access to comprehensive testing remain important challenges.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Medicine, University of Limerick, Limerick V94 T9PX, Munster, Ireland.
- Department of Oncology, College of Medicine, University of Saskatchewan, Saskatoon, SK S7N 5E5, Canada.
- Saskatchewan Cancer Agency, Regina, SK S4W 0G3, Canada.
ORCID-Profile: Ramy Habib, Erika Arnold, Franco J Vizeacoumar, Shahid Ahmed
Zitieren
APA
Habib, R., Arnold, E., Obi, T., Vizeacoumar, F. J., & Ahmed, S. (2026). Targeted Therapy in Pancreatic Ductal Adenocarcinoma: Current Advances and Challenges. Current Oncology, 33(8), 452. https://doi.org/10.3390/curroncol33080452
Vancouver
Habib R, Arnold E, Obi T, Vizeacoumar FJ, Ahmed S. Targeted Therapy in Pancreatic Ductal Adenocarcinoma: Current Advances and Challenges. Current Oncology. 2026;33(8):452. doi:10.3390/curroncol33080452
BibTeX
@article{Habib2026,
author = {Habib, Ramy and Arnold, Erika and Obi, Tasin and Vizeacoumar, Franco J and Ahmed, Shahid},
title = {Targeted Therapy in Pancreatic Ductal Adenocarcinoma: Current Advances and Challenges},
journal = {Current Oncology},
year = {2026},
volume = {33},
number = {8},
pages = {452},
doi = {10.3390/curroncol33080452}
}
EUVIMED